Reach Us +1-218-451-2974


Dersleri yüzünden oldukça stresli bir ruh haline sikiş hikayeleri bürünüp özel matematik dersinden önce rahatlayabilmek için amatör pornolar kendisini yatak odasına kapatan genç adam telefonundan porno resimleri açtığı porno filmini keyifle seyir ederek yatağını mobil porno okşar ruh dinlendirici olduğunu iddia ettikleri özel sex resim bir masaj salonunda çalışan genç masör hem sağlık hem de huzur sikiş için gelip masaj yaptıracak olan kadını gördüğünde porn nutku tutulur tüm gün boyu seksi lezbiyenleri sikiş dikizleyerek onları en savunmasız anlarında fotoğraflayan azılı erkek lavaboya geçerek fotoğraflara bakıp koca yarağını keyifle okşamaya başlar
Rescue Of TGF-b1 Signalling As A New Strategy For Neuroprotection In AD: Role Of Antidepressant Drugs | 21916
ISSN: 2161-0460

Journal of Alzheimers Disease & Parkinsonism
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Google Scholar citation report
Citations : 2590

Journal of Alzheimers Disease & Parkinsonism received 2590 citations as per Google Scholar report

Journal of Alzheimers Disease & Parkinsonism peer review process verified at publons
Indexed In
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Open J Gate
  • Genamics JournalSeek
  • Academic Keys
  • JournalTOCs
  • China National Knowledge Infrastructure (CNKI)
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • OCLC- WorldCat
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
Share This Page

Rescue of TGF-b1 signalling as a new strategy for neuroprotection in AD: Role of antidepressant drugs

2nd International Conference on Alzheimers Disease and Dementia

Filippo Caraci

ScientificTracks Abstracts: J Alzheimers Dis Parkinsonism

DOI: 10.4172/2161-0460.S1.006

Transforming-Growth-Factor-?1 (TGF-?1) is an anti-inflammatory cytokine that exerts neuroprotective effects against ?-amyloid (A?)-induced neurodegeneration. An impairment of TGF-?1 signaling pathway has been demonstrated in an early phase of Alzheimer?s disease (AD) pathogenesis. Deficit of TGF-?1 seems to be a common pathophysiological event both in depression and AD. Depressive symptoms may be among the earliest symptoms of preclinical stages of AD and a long-term treatment with antidepressants is known to reduce the risk to develop AD. Plasma TGF-?1 levels are reduced in depressed patients, and, interestingly, different second-generation antidepressants increase circulating TGF-?1 levels in depressed patients. Whereas these data identify TGF-?1 signaling as a potential common target for both depression and AD, the potential neuroprotective activity of antidepressants against A?-induced neurodegeneration in vitro has been only partially explored. We examined the neuroprotective activity of fluoxetine and sertraline both in pure and mixed rat neuronal cultures challenged with synthetic Ab(1-42) oligomers (100 nM) for 48 hours. We found that therapeutic concentrations (100 nM-1 ?M) of fluoxetine and sertraline significantly prevented A?-induced toxicity in mixed cultures, but not in pure neuronal cultures. A neutralizing antibody against TGF-?1 (2 ?g/ml) prevented the neuroprotective effects of antidepressant drugs against A?-induced neurodegeneration in mixed cultures. Consistent with a glia-mediated effect, a 24 hr treatment of astrocytes with fluoxetine promoted the release of active TGF-?1 in the culture media. Our data demonstrate that secondgeneration antidepressants are neuroprotective in vitro against A?-induced neurodegeneration by rescuing TGF-?1 signaling and suggest that these drugs might represent new neuroprotective tools for the treatment of AD.
Filippo Caraci is Assistant Professor of Psychopharmacology at the Department of Educational Sciences of the University of Catania. He has worked in the field of Neuropharmacology focusing his attention on the neurobiology of Alzheimer?s disease with the aim to identify new pharmacological targets. He has published more than 60 papers in peer reviewed journals and serving as referee for several international journals in the fields of pharmacology. He is an associate faculty member of F1000 and he is also Reviewing Editor of Frontiers in Experimental Pharmacology and Drug Discovery.